Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)

Annals of Oncology

Volumn 25, Issue 12, 2014, Pages 2363-2372

  von Minckwitz, Gunter ^a,b   Loibl, S ^a   Untch, M ^c   Eidtmann, H ^d   Rezai, M ^e   Fasching, P A ^f   Tesch, H ^g   Eggemann, H ^h   Schrader, I ⁱ   Kittel, K ^j   Hanusch, C ^k   Huober, J ^l   Solbach, C ^b   Jackisch, C ^m   Kunz, G ⁿ   Blohmer, J U ^o   Hauschild, M ^p   Fehm, T ^q   Nekljudova, V ^a   Gerber, B ^r  

^a German Breast Group   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Breast Center   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Department of Medical Oncology   (Germany)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ Henriettenstiftung   (Germany)

^j St Johannes Hospital ^*  (Germany)

^k Rotkreuzklinikum   (Germany)

^l UNIVERSITY HOSPITAL ULM   (Germany)

^m SANA KLINIKUM OFFENBACH   (Germany)

ⁿ ST JOHANNES HOSPITAL   (Germany)

^o St Gertrauden Hospital   (Germany)

^p Department of Senology   (Germany)

^q UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^r ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

more..

Author keywords

Bevacizumab; Disease free survival; Everolimus; Neoadjuvant chemotherapy; Overall survival

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EVEROLIMUS; PACLITAXEL; ANGIOGENESIS INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; RAPAMYCIN;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CONTROLLED STUDY; DRUG COMBINATION; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84927622456     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu455     Document Type: Article

References (15)

1. Kaufmann M, von Minckwitz G, Mamounas EP et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012; 19: 1508-1516.
2. von Minckwitz G, Blohmer JU, Costa SD et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2013; 31: 3623-3630.
3. von Minckwitz G, Kümmel S, Vogel P et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst 2008; 100: 552-562.
4. von Minckwitz G, Kümmel S, Vogel P et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008; 100: 542-551.
5. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309.
6. Huober J, Fasching PA, Hanusch C et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab-results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013; 49: 2284-93.
7. Untch M, Loibl S, Bischoff J et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012; 13: 135-144.
8. Gerber B, Loibl S, Eidtmann H et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the Geparquinto study (GBG 44). Ann Oncol 2013; 24: 2978-2984.
9. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-2132.
10. de Gramont A, Van Cutsem E, Schmoll HJ et al. Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233.
11. Miller K, O'Neill A, Dang C et al. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 2014; 32: (5 suppl); abstr 500).
12. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14: 933-942.
13. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
14. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172.
15. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640-647.